Monopar Therapeutics initiated with a Buy at BTIG

BTIG analyst Jeet Mukherjee initiated coverage of Monopar Therapeutics (MNPR) with a Buy rating and $87 price target The clinical stage biotechnology company is developing ALXN1840, a novel copper binding therapy for treatment of Wilson’s Disease, notes the analyst, who calls ‘1840 “an undervalued and underappreciated program by the Street.” While acknowledging the regulatory risk and “binary stock outlook” over the next 12-18 months as Monopar aims to submit an NDA in early 2026, the firm sees a “highly favorable benefit/risk ratio,” the analyst tells investors.